Drug search by name

Beleodaq and Hematologic toxicity

Result of checking the interaction of drug Beleodaq and disease Hematologic toxicity for safety when used together.

Check result:

Beleodaq <> Hematologic toxicity

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Belinostat can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia. It is recommended to monitor blood counts weekly during treatment, and modify dosage as necessary. It is recommended to monitor complete blood counts at baseline and weekly and to perform serum chemistry tests, including renal and hepatic functions prior to the start of the first dose of each cycle. Absolute neutrophil count (ANC) should be greater than or equal to 1.0 x 10 9/L and the platelet count should be greater than or equal to 50 x 10 9/L prior to the start of each cycle and prior to resuming treatment following toxicity. Discontinue belinostat in patients who have recurrent ANC nadirs less than 0.5 x 10 9/L and/or recurrent platelet count nadirs less than 25 x 10 9/L after two dosage reductions. Close monitoring is recommended.

Beleodaq

Generic Name: belinostat

Brand Name: Beleodaq

Synonyms: n.a.

What is Beleodaq?